Organoid forming potential as complementary parameter for accurate evaluation of breast cancer neoadjuvant therapeutic efficacy

期刊论文
发表日期：

2024年2月10日

查看全文

Hai-Shan Ye,
Dan Zhou,
Hong Li,
Jin Lv,
Hui-Qi Huang,
Jia-Jun She,
Jun-Hua Nie,
Ting-Ting Li,
Meng-Di Lu,
Bo-Le Du,
Shu-Qing Yang,
Pei-Xian Chen,
Sheng Li,
Guo-Lin Ye,
Wei Luo,
Jia Liu

摘要

Background

13–15% of breast cancer/BC patients diagnosed as pathological complete response/pCR after neoadjuvant systemic therapy/NST suffer from recurrence. This study aims to estimate the rationality of organoid forming potential/OFP for more accurate evaluation of NST efficacy.

Methods

OFPs of post-NST residual disease/RD were checked and compared with clinical approaches to estimate the recurrence risk. The phenotypes of organoids were classified via HE staining and ER, PR, HER2, Ki67 and CD133 immuno-labeling. The active growing organoids were subjected to drug sensitivity tests.

Results

Of 62 post-NST BC specimens, 24 were classified as OFP-I with long-term active organoid growth, 19 as OFP-II with stable organoid growth within 3 weeks, and 19 as OFP-III without organoid formation. Residual tumors were overall correlated with OFP grades (P < 0.001), while 3 of the 18 patients (16.67%) pathologically diagnosed as tumor-free (ypT0N0M0) showed tumor derived-organoid formation. The disease-free survival/DFS of OFP-I cases was worse than other two groups (Log-rank P < 0.05). Organoids of OFP-I/-II groups well maintained the biological features of their parental tumors and were resistant to the drugs used in NST.

Conclusions

The OFP would be a complementary parameter to improve the evaluation accuracy of NST efficacy of breast cancers.